言語を選択

MIF

MIF 詳細

英語名	Macrophage migration inhibitory factor	市販薬剤の数	1
治験薬の数	3	ターゲットの別称	EC:5.3.2.1，GIF，EC 5.3.3.12，EC 5.3.2.1，Macrophage Migration-Inhibitory Factors，Epididymis Secretory Sperm Binding Protein，EC:5.3.3.12，Phenylpyruvate Tautomerase，L-Dopachrome Tautomerase，MMIF，Glycosylation-inhibiting factor，L-dopachrome isomerase，MIF，Macrophage Migration Inhibitory Factor，Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor)，GLIF
研究＆開発段階	Approved

英語名	Macrophage migration inhibitory factor
ターゲットの別称	EC:5.3.2.1，GIF，EC 5.3.3.12，EC 5.3.2.1，Macrophage Migration-Inhibitory Factors，Epididymis Secretory Sperm Binding Protein，EC:5.3.3.12，Phenylpyruvate Tautomerase，L-Dopachrome Tautomerase，MMIF，Glycosylation-inhibiting factor，L-dopachrome isomerase，MIF，Macrophage Migration Inhibitory Factor，Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor)，GLIF
市販薬剤の数	1
治験薬の数	3
研究＆開発段階	Approved

MIF 製品リスト

属性
Protein (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
His Tag & Avi Tag (1)
マーカー
Biotin-labeled (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
MIF-H82E7	Human	HEK293	Biotinylated Human MIF Protein, His,Avitag™

総数量1

MIFバックグランド

Macrophage migration inhibitory factor(MIF) is also known as Glycosylation-inhibiting factor(GIF), L-dopachrome isomerase, L-dopachrome tautomerase, Phenylpyruvate tautomerase. Interacts with CXCR2 extracellular domain, CD74 extracellular domain, COPS5 and BNIPL. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.

MIF分子の別称

MIF,GLIF,MMIF,GIF

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
IPG-1094	IPG-1094; IPG-001	Phase 2 Clinical	Nanjing Immunophage Biotech Co Ltd	Brain metastases; Brain Neoplasms; Hematologic Neoplasms; Lupus Nephritis; Multiple Myeloma; Multiple Sclerosis; Psoriasis; Solid tumours	詳細
TRP2-electroporated autologous dendritic cell therapy (Memorial Sloan-Kettering)		Phase 1 Clinical	Memorial Sloan Kettering Cancer Center	Melanoma	詳細
STP-1	STP-1; STP1	Phase 1 Clinical	Stalicla Sa	Autism Spectrum Disorder	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Ibudilast	KC-404; AV-411; MN-166	Approved	Kyorin Pharmaceutical Co Ltd	Ketas, Pinatos, Eyevinal	Japan	Asthma; Multiple Sclerosis; Neuralgia	Kyorin Pharmaceutical Co Ltd		Alcoholism; Amyotrophic Lateral Sclerosis; Asthma; Diabetic Neuropathies; Headache Disorders, Secondary; HIV Infections; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuralgia; Opioid-Related Disorders; Pneumonia, Viral; Substance-Related Disorders	詳細

レビュー

S***n2023-04-28
0評価
Biotinylated Human MIF Protein, His,Avitag™
This product was used for characterization of a novel therapeutic testing kinetics and affinity on SPR with a Cytiva BiotinCAPture kit. It worked phenomenally with both the novel approach and a positive control. Additionally, it was used with a Streptavidin coated ELISA plate (also from Acro), results were phenomenal with that approach as well. Overall, this product has been well received by our team and we have already ordered more to continue testing.